NCT07288398Phase 3Active not recruiting

LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2

Study sponsor: Tenax Therapeutics, Inc. · TENX

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2028-06-30Estimated
Enrollment · participants540Estimated
Source updated2026-10-15Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Recruitment status changed

Before: Recruiting. After: Active not recruiting.

Check registry source